Care navigation that incorporated contingency management kept patients with methamphetamine use disorder engaged with a dedicated navigator but it did not significantly increase linkage to addiction treatment within 90 days.
For anyone researching addiction treatment options for stimulant use, the findings are a lesson in what engagement is worth when the system it connects to cannot hold the people it reaches.
The trial, called Beginning Early and Assertive Treatment for Methamphetamine Use, enrolled 192 participants at Denver Health, an integrated safety-net system in Colorado, between April 2023 and December 2024. The population reflects who arrives in acute care with meth-related problems.
The median age was 39 and of the 192 participants, 156 were male, 163, or 84.9%, were unstably housed, 158, or 82.3%, were unemployed, and 94, or 49%, lacked regular access to a working phone. More than half reported food insecurity and 70.8% said they often or frequently felt lonely or isolated.
How the Denver Care Navigation Trial Worked
Participants were randomized to dedicated care navigation incorporating contingency management, or to usual care. The intervention was built for the population it served.
A trained navigator completed an initial needs assessment then followed up weekly, helping with transportation, food and clothing, housing, disability applications, vital records, legal issues and vocational support. Participants without reliable phones were given pay-as-you-go mobile phones.
Contingency management came in the form of a digital prize wheel that participants could spin weekly with monetary prizes ranging from $5 to $50 and average total earnings of $58 over the study period.
Engagement was real. Of the 96 participants randomized to the intervention, 60, or 62.5%, had two or more navigation sessions with a median of five sessions each. Participants with unstable housing or no transportation would proactively seek out the navigator to meet and spin the wheel.
The Numbers Behind the Missed Primary Goal
The primary outcome was linkage to treatment within 30 and 90 days, defined as a substance use clinic visit, an outpatient behavioral health encounter, temporary residential treatment or self-reported treatment. On that measure the intervention did not move the needle.
Secondary outcomes told the same story with no differences in emergency department visits, overdose diagnoses, or mortality between the arms. Eight participants had at least one encounter involving an overdose diagnosis during the study period, and two died.
The one outcome where the intervention showed a genuine edge was study retention with 49.0% completing the 90-day study visit compared with 38.5% of the control group, and participants were more engaged with the navigator throughout. People stayed in touch. They did not, in statistically meaningful numbers, make it into treatment chairs.
Why Engagement Rose but Treatment Linkage Did Not
The participants carried enormous burdens with more than eight in ten unstably housed, most unemployed and nearly half lacking a working phone. A 90-day intervention may simply be too short to stabilize housing, income, and health before treatment becomes reachable.
The researchers also noted that many patients were still weighing whether they wanted to reduce their methamphetamine use at all, and that offering help before a person is ready can still plant a seed that pays off later.
The electronic health record data, available for every participant, showed a larger gap between arms than the composite measure did. It may mean the navigator moved people toward services inside the Denver Health system that self-reported data diluted.
The honest summary is that engagement improved, treatment linkage did not, and the gap between those two things is the finding.
Why Methamphetamine Needs Different Answers
Of the 309,274 overdose deaths reported in the US between January 2021 and June 2024, 31.2% involved methamphetamine, and 68.8% of those deaths also involved opioids. No FDA-approved medication exists for methamphetamine use disorder.
Contingency management, the reward-based behavioral intervention woven into this trial, has the strongest evidence base for stimulant use disorder, yet fewer than 10% of addiction treatment programs use it. Closing that gap matters, but this trial suggests incentives alone cannot substitute for treatment capacity, housing and time.
What This Means for Treatment Seekers
If you are researching drug rehab for methamphetamine use disorder, this study reframes a question worth asking any program. Not just whether they offer navigation or case management, but whether they can treat the whole situation a patient arrives with, including housing, mental health, and daily survival needs.
In this trial, two-thirds of participants had been diagnosed with a mental health condition, yet fewer than a third of those were receiving any treatment for it. Depression, anxiety, and trauma did not pause while patients waited for meth treatment to become reachable.
Engagement is not recovery. It is the doorway. This trial suggests the doorway is not the bottleneck. What sits behind it is.
Exploring Treatment Options
When comparing rehab centers for methamphetamine use disorder, look for programs that combine evidence-based behavioral therapy, including contingency management, with practical support services such as housing referrals, transportation help, case management, and mental health treatment for co-occurring conditions.
Ask how long the program works with patients before expecting traditional milestones, because this trial’s authors suggest methamphetamine recovery may operate on a longer clock than the 30- and 90-day windows used elsewhere.
Rehab.com’s directory includes verified treatment centers across the country. Call
800-985-8516
( 
Sponsored Helpline )
to speak with a treatment advisor about options for methamphetamine use disorder.
